Top analyst: 3 reasons to buy Merck right now

Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.
Kena Betancur | Getty Images

Alex Arfaei of BMO Capital Markets upgraded Merck to "outperform" Thursday morning in a note sent to clients.

He is one of the top analysts on Wall Street covering Merck and the pharmaceuticals sector. Arfaei's picks average a 17.6 percent one-year return with an 84 percent success rate, according to

Here's why he likes Merck now…